Expand BNTX Menu
BNTX MENU

BNTX Latest Press Releases

-- January 28, 2026 --

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer Globe Newswire 8:00 AM

-- January 14, 2026 --

The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era Globe Newswire 10:40 AM

-- January 12, 2026 --

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 6:45 AM

-- December 18, 2025 --

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field Globe Newswire 4:45 AM

-- December 9, 2025 --

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer Globe Newswire 7:00 AM

-- December 6, 2025 --

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer Globe Newswire 3:30 PM

-- December 3, 2025 --

BioNTech Achieves Minimum Condition in CureVac Exchange Offer Globe Newswire 9:01 AM

-- November 26, 2025 --

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration Globe Newswire 7:30 AM

-- November 3, 2025 --

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update Globe Newswire 6:45 AM

-- October 28, 2025 --

BioNTech to Host Innovation Series R&D Day on November 11, 2025 Globe Newswire 7:45 AM

-- October 27, 2025 --

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025 Globe Newswire 7:45 AM

-- October 22, 2025 --

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. Globe Newswire 6:45 AM

-- September 23, 2025 --

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025 Globe Newswire 6:45 AM

-- September 8, 2025 --

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity Globe Newswire 11:00 AM
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula Business Wire 6:45 AM
Market Data Delayed 15 Minutes